Ivan Kairatov stands at the intersection of biopharmaceutical innovation and clinical technology, bringing years of expertise in research and development to the forefront of oncology care. His work focuses on bridging the gap between raw medical data and actionable clinical insights, particularly for vulnerable populations like childhood cancer survivors. In this discussion, we explore the groundbreaking research from St. Jude Children’s Research Hospital regarding the use of large language models to transform patient-physician dialogue into a powerful tool for long-term health monitoring. We delve into the nuances of AI prompting, the hidden value within clinical transcripts, and the logistical shifts required to move these technologies from the laboratory to the bedside.
Clinical encounters often consist of up to 60% conversational data that remains untapped. How do you distinguish between routine patient updates and high-risk symptoms in these transcripts, and what specific metrics indicate a survivor needs immediate intervention?
When we sit in a clinical room, a staggering 40% to 60% of the encounter is essentially raw human dialogue that often disappears into the ether once the appointment ends. For childhood cancer survivors, this dialogue contains vital clues about how pain and fatigue ripple through their daily lives, long after the initial threat of the disease is gone. To distinguish a routine update from a high-risk symptom, we must look beyond the mere mention of a headache or tiredness and focus on the functional impact—specifically how these symptoms disrupt physical, cognitive, or social dimensions. In the recent study involving 30 survivors between the ages of 8 and 17, researchers analyzed more than 800 pieces of information from transcripts to identify those survivors whose symptoms were severe enough to require immediate, targeted support. It’s about catching that subtle tremor of exhaustion in a child’s voice or a caregiver’s description of a sudden social withdrawal that signals a deeper crisis requiring a physician’s intervention.
Basic instructions to large language models often yield unstable results when analyzing patient pain or fatigue. What are the logistical trade-offs of using “chain-of-thought” logic versus “generated knowledge” prompts, and how do these complex workflows improve accuracy?
Relying on a simple “zero-shot” prompt is like asking a doctor to diagnose a patient without ever opening their medical history; the results are often unstable and lack the nuance required for pediatric care. The logistical trade-off is that “chain-of-thought” logic requires the AI to slow down and articulate its reasoning through step-by-step logical instructions, which mimics the deliberate diagnostic process of a human expert but requires more computational time. Alternatively, “generated knowledge” prompts the model to first brainstorm and come up with relevant background information on cancer survivorship before it even looks at the patient’s specific transcript, creating a more informed context for the analysis. These sophisticated strategies showed a much higher concurrence with human reviewers because they don’t just guess; they build a logical bridge from the patient’s words to a specific clinical category of severity. Whether using models like ChatGPT or Llama, moving to these complex workflows ensures that the AI captures the “ripple effect” of treatment-related effects that occur long after the initial disease is cured.
Integrating AI into the clinical workflow requires moving from proof-of-concept to real-time decision support. What step-by-step process should a physician follow to validate AI findings against their own observations, and what are the risks of relying on simpler “zero-shot” AI prompts?
Moving from a proof-of-concept to real-time clinical support requires a rigorous validation process where the physician acts as the final arbiter of truth, ensuring the technology serves the patient rather than replaces human judgment. First, a clinician should review the AI’s categorization—such as the specific severity of fatigue or cognitive impact—against their own direct observations of the survivor and the caregiver’s qualitative reports. The inherent risk of relying on “zero-shot” or “few-shot” prompts is their tendency to produce inaccurate results because they provide no or minimal information beyond basic instructions, potentially leading to missed opportunities for intervention. To validate effectively, a physician should treat the AI output as a draft summary, comparing it against the “gold-standard” of human expert analysis to ensure the model isn’t oversimplifying complex pain patterns. This creates a vital safety net, allowing the AI to unlock hidden data in physician-patient conversations while the doctor focuses on the emotional and sensory nuances that a machine might still struggle to fully grasp.
Childhood cancer survivors face physical and cognitive disruptions long after their initial treatment ends. How can automated symptom analysis better capture the nuanced social impacts of fatigue in young patients, and what practical steps should clinics take to ensure this leads to personalized care?
While AI is increasingly adept at identifying physical and cognitive disruptions, capturing the “social impact” of fatigue in a 12-year-old—such as no longer having the energy to play with friends—requires a more moderate and careful approach than identifying purely physical symptoms. Automated analysis can highlight these subtle shifts by scanning thousands of words in transcripts for mentions of missed school days or decreased peer interaction, details that are often buried in long-form answers to open-ended questions. For clinics to turn this into personalized care, they must take the practical step of integrating these AI insights directly into the clinical workflow, so that a high-risk flag for “social disruption” triggers an immediate referral to a social worker or psychologist. This proactive approach ensures that the data informs real-time decision-making, helping physicians identify which survivors among the growing population need that extra, targeted support to navigate life after cancer. We must treat every word a caregiver says during an interview as a potential data point that, when analyzed correctly, can lead to a significant improvement in the survivor’s long-term quality of life.
What is your forecast for the role of conversational AI in long-term survivorship care?
I forecast that conversational AI will eventually become the “silent partner” in every survivorship clinic, acting as a persistent memory for patients who may be seen by their medical team only once a year. We will see these models evolve from simple text analysis to real-time assistants that can flag high-risk symptoms the moment a transcript is generated, ensuring no child falls through the cracks of a busy medical system. As we refine strategies like chain-of-thought and generated knowledge prompting, the accuracy of these models will reach a point where AI can predict functional decline months before it becomes debilitating for the patient. Ultimately, this technology will liberate physicians from the heavy lifting of reviewing hundreds of pages of survey data and conversational notes, allowing them to return to the heart of medicine: the human connection and the art of healing. It is a future where the 60% of data we currently ignore becomes the very foundation of long-term wellness for every cancer survivor.
